Anaprox in dysmenorrhea: reduction of pain and intrauterine pressure.
In a double-blind parallel trial, 24 dysmenorrheic women received a single dose of Anaprox (1,100 mg) or placebo. Over the next 2 hours, pain intensity was scored and intrauterine pressure was measured using an immobilized microballoon. At the end of 2 hours, all 11 patients given Anaprox (but only three of the 13 given placebo) experienced complete pain relief (p = 0.0004). The resting intrauterine pressure (IUP) decreased from a mean of 51.4 to 26.8 mm Hg in the Anaprox-treated group, while in the placebo group the mean resting IUP values remained essentially unchanged ( drop from 55.4 to 51.9 mm Hg was observed). This difference between the two treatment groups was statistically significant in favor of Anaprox (p = 0.03). Several patients from each group were given 0.2 mg of ergonovine by intramuscular injection following the 2 hour trial. In both groups, the resting IUP increased within 30 minutes; the corresponding increase in pain intensity was more pronounced, however, in the placebo group. These results support the premise that a decrease in resting IUP is directly linked to the pain-relieving effects of Anaprox.
D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D004341:Drug Evaluation; D004412:Dysmenorrhea / Q000188:drug therapy*; D004874:Ergonovine / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D009215:Myometrium / Q000187:drug effects*; D009288:Naproxen / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010146:Pain; D010919:Placebos; D011312:Pressure; D014599:Uterus / Q000187:drug effects*
D010919:Placebos; D009288:Naproxen; D004874:Ergonovine